Literature DB >> 25237241

Essence of the revised guideline for the management of hyperuricemia and gout.

Hisashi Yamanaka1, The Guideline Revising Committee Of Japanese Society Of Gout And Nucleic Acid Metabolism1.   

Abstract

Hyperuricemia and gout are common diseases that can be treated by general and family physicians, but with the wide range of diagnosis and treatment departments that treat them, these are diseases for which guidelines are demonstrably useful. Published in 2002 by the Japanese Society of Gout and Nucleic Acid Metabolism in 2002, the Guideline for the Management of Hyperuricemia and Gout was subsequently revised, and in January 2010 the Revised Guideline for the Management of Hyperuricemia and Gout was published. While maintaining the spirit of the original guideline, the revised guideline not only fulfills the prerequisites required for formulating the current guideline but also incorporates new approaches such as the quantification of consensus levels. In addition to emphasizing that hyperuricemia has the duel aspects of being a urate deposition disease and a disease associated with lifestyle diseases, as well as the fact that all hyperuricemia patients require correction of lifestyle habits related to obesity, hypertension, and metabolic syndrome, the revised guideline covers the current evidence in detail. It is the author's sincere hope that this guideline will be utilized effectively in daily medical practice in this field.

Entities:  

Keywords:  Consensus; Evidence; Recommendation level; Uric acid

Year:  2012        PMID: 25237241

Source DB:  PubMed          Journal:  Japan Med Assoc J        ISSN: 1346-8650


  22 in total

1.  Diagnostic Accuracy of Single Spot Urine for Detecting Renal Uric Acid Underexcretion in Men.

Authors:  Naoki Sakane; Ayana Okuno; Kouji Nomaguchi; Miyuki Tanaka; Fumiaki Abe; Izumi Kakiuchi; Kyoko Kiyosawa; Mitsunaga Miyasaka; Masahiko Nakamura
Journal:  J Clin Med Res       Date:  2020-06-25

2.  Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia.

Authors:  Hirotake Okazaki; Akihiro Shirakabe; Nobuaki Kobayashi; Noritake Hata; Takuro Shinada; Masato Matsushita; Yoshiya Yamamoto; Yusaku Shibata; Junsuke Shibuya; Reiko Shiomura; Suguru Nishigoori; Kuniya Asai; Wataru Shimizu
Journal:  Heart Vessels       Date:  2016-09-26       Impact factor: 2.037

3.  Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.

Authors:  Na Lu; Sharan K Rai; Robert Terkeltaub; Seoyoung C Kim; Mariano E Menendez; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2016-03-31       Impact factor: 5.532

4.  Serum uric acid as a prognostic marker in the setting of advanced vascular disease: a prospective study in the elderly.

Authors:  Giuseppe Di Stolfo; Sandra Mastroianno; Domenico Rosario Potenza; Giovanni De Luca; Carmela d'Arienzo; Michele Antonio Pacilli; Mario Fanelli; Aldo Russo; Raffaele Fanelli
Journal:  J Geriatr Cardiol       Date:  2015-09       Impact factor: 3.327

5.  Effect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort Study.

Authors:  Jiunn-Horng Chen; Joung-Liang Lan; Chi-Fung Cheng; Wen-Miin Liang; Hsiao-Yi Lin; Gregory J Tsay; Wen-Ting Yeh; Wen-Harn Pan
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

6.  Lifestyle-related diseases following the evacuation after the Fukushima Daiichi nuclear power plant accident: a retrospective study of Kawauchi Village with long-term follow-up.

Authors:  Daniel K Ebner; Megumi Ohsawa; Keiko Igari; Kouji H Harada; Akio Koizumi
Journal:  BMJ Open       Date:  2016-07-11       Impact factor: 2.692

Review 7.  An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.

Authors:  Marilisa Bove; Arrigo Francesco Giuseppe Cicero; Maddalena Veronesi; Claudio Borghi
Journal:  Vasc Health Risk Manag       Date:  2017-02-08

Review 8.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

9.  Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial.

Authors:  Mohd Noor Azreey Mukri; Wei-Yen Kong; Ruslinda Mustafar; Syahrul Sazliyana Shaharir; Shamsul Azhar Shah; Abdul Halim Abdul Gafor; Rozita Mohd; Rizna Abdul Cader; Lydia Kamaruzaman
Journal:  EXCLI J       Date:  2018-06-13       Impact factor: 4.068

10.  Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.